Iovance Cell Therapy Revenue Jumps 80%

Growing Amtagvi sales narrow losses for a commercial-stage melanoma treatment already on the market.

Updated on Nov. 6, 2026 in Biotech

Stainless-steel bioreactor vessels and clear tubing in a clean, softly lit biomanufacturing room, with a translucent cell-culture bag suspended in the foreground. — Iovance Biotherapeutics reported third-quarter revenue of $121.5 million, up 80%, as demand for its melanoma cell therapy Amtagvi narrowed losses. AI Illustration. Upload story photo >

Iovance Biotherapeutics reported third-quarter 2026 revenue of $121.469 million, up 80% from $67.455 million a year earlier, for the quarter ended September 30, 2026. The company's results are reported, not a new product launch; Amtagvi, its approved treatment for previously treated advanced melanoma, is already on the market.

Why it matters

The revenue growth was driven by continued U.S. demand for Amtagvi, a cell-based therapy built on tumor-infiltrating lymphocytes, immune cells taken from a patient's own tumor and expanded before reinfusion. Revenue growth alongside a narrowing net loss suggests a commercial-stage cell therapy is moving toward sustained scale.

The company reported a record gross margin alongside revenue of about $122 million in the quarter, with U.S. Amtagvi contributing about $102 million and global Proleukin about $20 million. Iovance's own filing describes the margin as its highest ever, but the extraction does not break down the cost drivers behind it.

The players

Iovance Biotherapeutics

A clinical-stage cell-therapy company focused on tumor-infiltrating lymphocyte therapies, whose lead commercial product is Amtagvi.

The details

Amtagvi is built on tumor-infiltrating lymphocytes (TILs), immune cells harvested from a patient's tumor, grown in the lab in large numbers, and infused back to target cancer. Proleukin, a separate interleukin-2 product, contributes a smaller revenue share outside the U.S. Iovance's focus is on this cell-therapy platform rather than on small-molecule drugs.

Q3 2025 served as the prior-year comparison period for revenue and net loss.
The quarter ended September 30, 2026, with a cash position of about $382 million.
Iovance expects total product revenue of $410 million to $420 million in 2026.
The company expects its cash to fund operations well into 2029.

The Tech Race

Amtagvi is a cell therapy, a category that competes with antibody and small-molecule oncology drugs for the same advanced-melanoma patients. Iovance's revenue growth shows a cell therapy reaching commercial scale in a field where most approved cancer drugs are not personalized cell products.

Amtagvi is available to eligible patients with previously treated advanced melanoma in the United States. The extraction does not give pricing or access timelines beyond the reported 2026 revenue target.

The takeaway

Revenue growth and a narrowing loss point to a cell therapy reaching commercial scale. Watch whether Iovance meets its $410-420 million 2026 product revenue target in the next annual results.